The emerging retatrutide provider landscape is significantly shifting , presenting complexities for pharmaceutical companies . Currently, the count of established suppliers is relatively limited , primarily focused on contract manufacturing organizations (CMOs) . Regional presence is predominantly located in the East , with increasing presence from